Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC
Sponsor: Louisiana State University Health Sciences Center in New Orleans
This PHASE2 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. Louisiana State University Health Sciences Center in New Orleans leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2017 — Aug 2017 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Louisiana State University Health Sciences Center in New Orleans
- Mayo Clinic
- National Cancer Institute (NCI)
- Providence Cancer Center, Earle A. Chiles Research Institute
- Providence Health & Services
- UbiVac
For direct contact, visit the study record on ClinicalTrials.gov .